Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | GZMB | P10144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399597 | 1.00 | F2 (0.45) | F2NMUR2NMUR1ACEREN | |
| SCHEMBL15485412 | 0.89 | F2 (0.41) | F2NMUR2NMUR1ACENTSR2 | |
| SCHEMBL29946190 | 0.87 | GZMB (0.52) | F2ACERENNTSR2NTSR1 | |
| SCHEMBL30657490 | 0.84 | CALCRL (0.43) | F2RENCAPN1 | |
| SCHEMBL29726608 | 0.84 | CALCRL (0.44) | F2RENCAPN1KEAP1 | |
| SCHEMBL16081611 | 0.83 | F2 (0.40) | F2NMUR2NMUR1ACEREN | |
| SCHEMBL30657491 | 0.81 | F2 (0.42) | F2NTSR2NTSR1 | |
| SCHEMBL30657497 | 0.80 | CALCRL (0.44) | RENCAPN1 | |
| SCHEMBL29946268 | 0.80 | TASP1 (0.51) | — | |
| SCHEMBL30434738 | 0.78 | NTSR2 (0.46) | F2NMUR2ACERENCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014139014-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY AND VASCULAR PERMEABILITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-18 | — | — | WO | claimed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | claimed |
| EP-2648735-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | The University Of British Columbia (CA) | 2013-10-16 | — | — | EP | claimed |
| WO-2012076985-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-06-14 | — | — | WO | claimed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-20240376517-A1 | GRANZYME B DETECTION | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2024-11-14 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240301352-A1 | METHOD FOR PRODUCING CAR-T CELLS | AGC Inc. (JP) | 2024-09-12 | — | — | US | disclosed |
| EP-4428229-A1 | METHOD FOR PRODUCING CAR-T CELLS | AGC INC. (JP) | 2024-09-11 | — | — | EP | disclosed |
| US-20240268372-A1 | Methods and Compositions for Extending Organ and Tissue Preservation | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2014139014-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY AND VASCULAR PERMEABILITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | disclosed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | disclosed |
| EP-2648735-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | The University Of British Columbia (CA) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076985-A2 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-06-14 | — | — | WO | disclosed |
| EP-2205278-A1 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS | The University of British Columbia (CA) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009055934-A1 | TREATMENT OF FIBRILLINOPATHY OR ELASTINOPATHY USING GRANZYME INHIBITORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009043170-A1 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | F2 3828/4885NMUR2 1846/4885NMUR1 1956/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | F2 3828/4885NMUR2 1846/4885NMUR1 1956/4885 |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | GZMB, PRF1, SERPINB1 | F2 2320/4885NMUR2 2547/4885NMUR1 2388/4885 |
| US-20240376517-A1 | GRANZYME B DETECTION | GZMB, CTSB, DNASE1L3 | F2 2290/4885NMUR2 1495/4885NMUR1 1456/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | F2 3828/4885NMUR2 1846/4885NMUR1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.